Yehao Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yehao Sun has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Irfan Rahman
Department of Environmental Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
15 shared publications - Dongmei Li
Department of Clinical and Translational Research, University of Rochester Medical Center, Rochester, NY, USA
8 shared publications - Scott McIntosh
Department of Public Health Sciences, University of Rochester Medical Center, Rochester, NY, USA
6 shared publications - Felix Effah
Department of Environmental Medicine, University of Rochester Medical Center, Rochester, NY, USA
4 shared publications - Prital Prabhu
Department of Environmental Medicine, University of Rochester Medical Center, Rochester, NY, United States
4 shared publications - Karen Lin
Department of Environmental Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
3 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by MDPI AG in Preprints.org
Design-Specific New Approach Methodology Using Air-Liquid Interface (ALI) for Toxicological Testing
Air-liquid interface (ALI) cultures of pulmonary cells, such as human bronchial epithelial cells (HBECs) are widely used to study airway biology, disease mechanisms, therapeutic interventions, and toxico-pharmacological properties of drugs. We hypothesized that differentiation-dependent temporal shifts in epithelial phenotype result in distinct windows of biological responsiveness, and that pathway-specific transcriptional signatures can be leveraged to identify optimal intervention time points within ALI cultures using design-specific New Approach Methodology (NAM). We conducted a targeted genetic screening of key markers involved in DNA damage responses and inflammatory pathways. In addition, we measured the transepithelial electrical resistance (TEER) as a proxy for tight junction formation. By analyzing the temporal expression profiles of these genes at multiple time points (Day 0, 7, 14, and 21), we identified biologically relevant differentiation stages for experimental interventions. To the best of our knowledge, this is the first time such a recommendation has been proposed for ALI studies for toxicological testing. We propose a data-driven strategy to determine the optimal experimental window based on pathway-specific gene expression. This novel approach may enhance the reproducibility and accuracy of airway disease modelling, toxicity and drug testing, ensuring that studies are conducted at the most functionally relevant stage of differentiation.
- 10 November 2026
- Published by MDPI AG in Preprints.org
Open AccessDesign-Specific New Approach Methodology Using Air-Liquid Interface (ALI) for Toxicological Testing
Air-liquid interface (ALI) cultures of pulmonary cells, such as human bronchial epithelial cells (HBECs) are widely used to study airway biology, disease mechanisms, therapeutic interventions, and toxico-pharmacological properties of drugs. We hypothesized that differentiation-dependent temporal shifts in epithelial phenotype result in distinct windows of biological responsiveness, and that pathway-specific transcriptional signatures can be leveraged to identify optimal intervention time points within ALI cultures using design-specific New Approach Methodology (NAM). We conducted a targeted genetic screening of key markers involved in DNA damage responses and inflammatory pathways. In addition, we measured the transepithelial electrical resistance (TEER) as a proxy for tight junction formation. By analyzing the temporal expression profiles of these genes at multiple time points (Day 0, 7, 14, and 21), we identified biologically relevant differentiation stages for experimental interventions. To the best of our knowledge, this is the first time such a recommendation has been proposed for ALI studies for toxicological testing. We propose a data-driven strategy to determine the optimal experimental window based on pathway-specific gene expression. This novel approach may enhance the reproducibility and accuracy of airway disease modelling, toxicity and drug testing, ensuring that studies are conducted at the most functionally relevant stage of differentiation.
- 31 January 2026
- Published by Elsevier in Toxicology
- Vol. 522, 154421
A comparative toxicological evaluation of nicotine and its analog 6-methyl nicotine in E-cigarette aerosol utilizing a 3D in vitro human respiratory model
- 31 January 2026
- Published by Elsevier in Toxicology
- Vol. 522, 154421
A comparative toxicological evaluation of nicotine and its analog 6-methyl nicotine in E-cigarette aerosol utilizing a 3D in vitro human respiratory model
- Open Access
- 9 January 2026
- Published by Elsevier in Toxicology Reports
- Vol. 16, 102202
Toxicity and health effects of delta-8, delta-9, and delta-10-tetrahydrocannabinol and unregulated cannabinoids in vaping products
- 9 January 2026
- Published by Elsevier in Toxicology Reports
- Vol. 16, 102202
Open AccessToxicity and health effects of delta-8, delta-9, and delta-10-tetrahydrocannabinol and unregulated cannabinoids in vaping products
- Open Access
- 21 November 2025
- Published by Elsevier in Toxicology Reports
- Vol. 15
Cytotoxic and oxidative effects of commercially available propylene glycol (PG) and vegetable glycerin (VG): Common humectants in electronic cigarettes
- 21 November 2025
- Published by Elsevier in Toxicology Reports
- Vol. 15
Open AccessCytotoxic and oxidative effects of commercially available propylene glycol (PG) and vegetable glycerin (VG): Common humectants in electronic cigarettes
- 1 October 2025
- Published by Elsevier in Toxicology Letters
- Vol. 413, 111739
Toxicity of humectants propylene glycol and vegetable glycerin in electronic nicotine delivery systems
- 1 October 2025
- Published by Elsevier in Toxicology Letters
- Vol. 413, 111739
Toxicity of humectants propylene glycol and vegetable glycerin in electronic nicotine delivery systems
- Open Access
- 12 September 2025
- Published by MDPI AG in Preprints.org
Health Effects of Delta-8, Delta-9, and Delta-10-Tethydrocannabinol and New Unregulated THC Vaping Products
Hemp-derived cannabinoids (CBDs) such as Δ8- and Δ10-tetrahydrocannabinol (THC) in cannabis e-cigarettes have been growing in popularity among youth, causing a great concern for their health effects. Previous novel lung injury outbreaks, namely E-cigarette or Vaping Use-Associated Lung Injury (EVALI), were associated with the rising use of e-cigarettes and vaping products. Toxicological studies have revealed that chronic exposure to cannabis vapor can cause adverse brain and pulmonary effects. Federal regulatory policies like the United States 2018 Farm Bill classify hemp as cannabis and set a limit of no more than 0.3% Δ9-THC, while products containing more than 0.3% are defined as ‘marijuana.’ This regulatory loophole has led to the proliferation of hemp-derived intoxicating cannabinoids, such as Δ8- and Δ10-THC, in addition to cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG) and Δ9-THC appearing in combination products on the market. This phenomenon poses significant health risks to youth because these newer THC isomers and products are currently unregulated and not well-researched, yet they are still widely available. Therefore, we have examined the potential therapeutical uses, toxicity, pharmacology, and possible health risks of several THC and hemp-derived cannabinoids. This review also draws insightful highlights to the public health consequences of secondary exposures to CBD and THC, and their molecular mechanisms of actions. It underscores the urgency for a strict regulatory oversight over unregulated cannabinoid markets to prevent other vaping-related health crises and other rapidly emerging cannabis health disorders, like the cannabinoid hyperemesis syndrome (CHS).
- 12 September 2025
- Published by MDPI AG in Preprints.org
Open AccessHealth Effects of Delta-8, Delta-9, and Delta-10-Tethydrocannabinol and New Unregulated THC Vaping Products
Hemp-derived cannabinoids (CBDs) such as Δ8- and Δ10-tetrahydrocannabinol (THC) in cannabis e-cigarettes have been growing in popularity among youth, causing a great concern for their health effects. Previous novel lung injury outbreaks, namely E-cigarette or Vaping Use-Associated Lung Injury (EVALI), were associated with the rising use of e-cigarettes and vaping products. Toxicological studies have revealed that chronic exposure to cannabis vapor can cause adverse brain and pulmonary effects. Federal regulatory policies like the United States 2018 Farm Bill classify hemp as cannabis and set a limit of no more than 0.3% Δ9-THC, while products containing more than 0.3% are defined as ‘marijuana.’ This regulatory loophole has led to the proliferation of hemp-derived intoxicating cannabinoids, such as Δ8- and Δ10-THC, in addition to cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG) and Δ9-THC appearing in combination products on the market. This phenomenon poses significant health risks to youth because these newer THC isomers and products are currently unregulated and not well-researched, yet they are still widely available. Therefore, we have examined the potential therapeutical uses, toxicity, pharmacology, and possible health risks of several THC and hemp-derived cannabinoids. This review also draws insightful highlights to the public health consequences of secondary exposures to CBD and THC, and their molecular mechanisms of actions. It underscores the urgency for a strict regulatory oversight over unregulated cannabinoid markets to prevent other vaping-related health crises and other rapidly emerging cannabis health disorders, like the cannabinoid hyperemesis syndrome (CHS).
- Open Access
- 16 May 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (20)
Molecular determinants of sialylated IgG anti-inflammatory activity
IgG antibodies are the basis for many successful therapeutics. A single, N-linked glycan is present on the Fc on all IgGs, and the composition of that glycan exerts marked influence over effector functions of the IgG. We and others have shown terminal sialylation of the Fc glycan confers anti-inflammatory activity to the IgG1 subclass and is thought to be responsible for the anti-inflammatory activity of high-dose intravenous immunoglobulin. However, whether sialylation results in anti-inflammatory activity for other IgG subclasses is unknown. We found that IgG1 and IgG3, but not IgG2 nor IgG4, suppressed autoantibody-mediated inflammation in vivo when sialylated. This activity was dependent upon human DC-SIGN or its murine ortholog, SIGN-R1. Fc γ receptor-binding profiles for asialylated and sialylated IgG subclasses reinforced these similarities, with IgG1 and IgG3 sharing binding patterns. Amino acid sequence alignments identified two uniquely conserved amino acid residues at positions 234 and 327 of the CH2 domain of all human IgG1 and IgG3 allotypes that were distinct from IgG2 and IgG4. Indeed, molecular modeling of the shared residues in IgG1 and IgG3 revealed a hydrophobic-heavy interchain interaction that was not present in IgG2 nor IgG4. Introduction of those IgG1/3 residues into an IgG4-Fc resulted in anti-inflammatory activity in vivo when sialylated. Conversely, a reciprocal sialylated IgG1 mutant with IgG2/4 residues lacked anti-inflammatory activity. These results define the amino acid requirements of anti-inflammatory sialylated IgG and enable rational amino acid and glycan engineering across all therapeutic IgG subclasses.
- 16 May 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (20)
Open AccessMolecular determinants of sialylated IgG anti-inflammatory activity
IgG antibodies are the basis for many successful therapeutics. A single, N-linked glycan is present on the Fc on all IgGs, and the composition of that glycan exerts marked influence over effector functions of the IgG. We and others have shown terminal sialylation of the Fc glycan confers anti-inflammatory activity to the IgG1 subclass and is thought to be responsible for the anti-inflammatory activity of high-dose intravenous immunoglobulin. However, whether sialylation results in anti-inflammatory activity for other IgG subclasses is unknown. We found that IgG1 and IgG3, but not IgG2 nor IgG4, suppressed autoantibody-mediated inflammation in vivo when sialylated. This activity was dependent upon human DC-SIGN or its murine ortholog, SIGN-R1. Fc γ receptor-binding profiles for asialylated and sialylated IgG subclasses reinforced these similarities, with IgG1 and IgG3 sharing binding patterns. Amino acid sequence alignments identified two uniquely conserved amino acid residues at positions 234 and 327 of the CH2 domain of all human IgG1 and IgG3 allotypes that were distinct from IgG2 and IgG4. Indeed, molecular modeling of the shared residues in IgG1 and IgG3 revealed a hydrophobic-heavy interchain interaction that was not present in IgG2 nor IgG4. Introduction of those IgG1/3 residues into an IgG4-Fc resulted in anti-inflammatory activity in vivo when sialylated. Conversely, a reciprocal sialylated IgG1 mutant with IgG2/4 residues lacked anti-inflammatory activity. These results define the amino acid requirements of anti-inflammatory sialylated IgG and enable rational amino acid and glycan engineering across all therapeutic IgG subclasses.
- 1 February 2025
- Published by Elsevier in Toxicology Letters
- Vol. 405, 9-15
Emerging nicotine analog 6-methyl nicotine increases reactive oxygen species in aerosols and cytotoxicity in human bronchial epithelial cells
- 1 February 2025
- Published by Elsevier in Toxicology Letters
- Vol. 405, 9-15
Emerging nicotine analog 6-methyl nicotine increases reactive oxygen species in aerosols and cytotoxicity in human bronchial epithelial cells
- Open Access
- 3 October 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Vaping Greed, Perception, and Addiction (Preprint)
BACKGROUND The greed of e-cigarette manufacturers including economic, capitalist, incentive, cultural, moral, psychological, and philosophical dimensions, contributed to the origin and development of vaping greed and shaped users' behaviors. OBJECTIVE Vaping greed is manifested in the large market share taken by the companies, but these all significantly harm users' health and the communities. METHODS This is involved via social media perception of adolescents and teenagers as an individual or in a group. The addiction could be transgenerational and can induce trauma both at an individual level and a community level RESULTS It is important to identify the greed and public health perceptions, and measures are taken to treat the symptoms of the greed by educating the users and making them aware of their unfulfilled needs to regain authenticity and establish an infallible authority to enforce universal morality. CONCLUSIONS This will eradicate the complications of addiction and the root of such capitalists’ greed for tobacco/nicotine perception, addiction, and marketing.
- 3 October 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessVaping Greed, Perception, and Addiction (Preprint)
BACKGROUND The greed of e-cigarette manufacturers including economic, capitalist, incentive, cultural, moral, psychological, and philosophical dimensions, contributed to the origin and development of vaping greed and shaped users' behaviors. OBJECTIVE Vaping greed is manifested in the large market share taken by the companies, but these all significantly harm users' health and the communities. METHODS This is involved via social media perception of adolescents and teenagers as an individual or in a group. The addiction could be transgenerational and can induce trauma both at an individual level and a community level RESULTS It is important to identify the greed and public health perceptions, and measures are taken to treat the symptoms of the greed by educating the users and making them aware of their unfulfilled needs to regain authenticity and establish an infallible authority to enforce universal morality. CONCLUSIONS This will eradicate the complications of addiction and the root of such capitalists’ greed for tobacco/nicotine perception, addiction, and marketing.
- Open Access
- 27 May 2024
- Published by JMIR Publications Inc. in Online Journal of Public Health Informatics
- Vol. 16 (1) , e51991
e-Cigarette Tobacco Flavors, Public Health, and Toxicity: Narrative Review
Background: Recently, the US Food and Drug Administration implemented enforcement priorities against all flavored, cartridge-based e-cigarettes other than menthol and tobacco flavors. This ban undermined the products’ appeal to vapers, so e-cigarette manufacturers added flavorants of other attractive flavors into tobacco-flavored e-cigarettes and reestablished appeal. Objective: This review aims to analyze the impact of the addition of other flavorants in tobacco-flavored e-cigarettes on both human and public health issues and to propose further research as well as potential interventions. Methods: Searches for relevant literature published between 2018 and 2023 were performed. Cited articles about the toxicity of e-cigarette chemicals included those published before 2018, and governmental websites and documents were also included for crucial information. Results: Both the sales of e-cigarettes and posts on social media suggested that the manufacturers’ strategy was successful. The reestablished appeal causes not only a public health issue but also threats to the health of individual vapers. Research has shown an increase in toxicity associated with the flavorants commonly used in flavored e-cigarettes, which are likely added to tobacco-flavored e-cigarettes based on tobacco-derived and synthetic tobacco-free nicotine, and these other flavors are associated with higher clinical symptoms not often induced solely by natural, traditional tobacco flavors. Conclusions: The additional health risks posed by the flavorants are pronounced even without considering the toxicological interactions of the different tobacco flavorants, and more research should be done to understand the health risks thoroughly and to take proper actions accordingly for the regulation of these emerging products.
- 27 May 2024
- Published by JMIR Publications Inc. in Online Journal of Public Health Informatics
- Vol. 16 (1) , e51991
Open Accesse-Cigarette Tobacco Flavors, Public Health, and Toxicity: Narrative Review
Background: Recently, the US Food and Drug Administration implemented enforcement priorities against all flavored, cartridge-based e-cigarettes other than menthol and tobacco flavors. This ban undermined the products’ appeal to vapers, so e-cigarette manufacturers added flavorants of other attractive flavors into tobacco-flavored e-cigarettes and reestablished appeal. Objective: This review aims to analyze the impact of the addition of other flavorants in tobacco-flavored e-cigarettes on both human and public health issues and to propose further research as well as potential interventions. Methods: Searches for relevant literature published between 2018 and 2023 were performed. Cited articles about the toxicity of e-cigarette chemicals included those published before 2018, and governmental websites and documents were also included for crucial information. Results: Both the sales of e-cigarettes and posts on social media suggested that the manufacturers’ strategy was successful. The reestablished appeal causes not only a public health issue but also threats to the health of individual vapers. Research has shown an increase in toxicity associated with the flavorants commonly used in flavored e-cigarettes, which are likely added to tobacco-flavored e-cigarettes based on tobacco-derived and synthetic tobacco-free nicotine, and these other flavors are associated with higher clinical symptoms not often induced solely by natural, traditional tobacco flavors. Conclusions: The additional health risks posed by the flavorants are pronounced even without considering the toxicological interactions of the different tobacco flavorants, and more research should be done to understand the health risks thoroughly and to take proper actions accordingly for the regulation of these emerging products.